The effects of agomelatine on sexual function in depressed patients and healthy volunteers
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background: Selective serotonin reuptake inhibitor (SSRI) and serotonin and norepinephrine reuptake inhibitor antidepressants are associated with high rates of treatment‐emergent sexual dysfunction (TESD) due to stimulation of serotonin receptors. Objective: The objective is to evaluate the effect of agomelatine on sexual function in depressed patients. Methods: This paper reviews published and unpublished data on sexual function with agomelatine in depressed patients and healthy volunteers. Results: Agomelatine, an agonist of melatonergic MT1 and MT2 receptors and antagonist of 5‐HT2 receptors, is associated with similar rates of sexual dysfunction compared with placebo and lower rates compared with other antidepressants. Twice as many sexually active depressed patients (n = 193) reported a deterioration of sexual function during 12 weeks of treatment with venlafaxine compared with agomelatine (15.2% vs. 8.2%, p < 0.0001); however, no differences were found with respect to arousal. Using the Arizona Sexual Experience Scale in depressed patients (n = 399), the incidence of treatment‐emergent sexual dysfunction (TESD) with agomelatine (3%) was significantly lower than placebo (8.6%) and selective serotonin reuptake inhibitors (10.1%). Among healthy male volunteers (n = 92), TESD was not increased compared with placebo in either agomelatine (25 and 50 mg/day) group over 8 weeks, and both were significantly lower than TESD with paroxetine (p < 0.0001). Moderate or severe TESD occurred in less than 5% of subjects receiving agomelatine versus 62% who received paroxetine (p < 0.001). Conclusion: Agomelatine demonstrates favorable sexual acceptability. Copyright © 2011 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Sexual Dysfunction Among Newer Antidepressants
Clayton, A. H., Pradko, J. F., Croft, H. A., Montano, C. B., Leadbetter, R. A., Bolden-Watson, C., Bass, K. I., Donahue, R. M. J., Jamerson, B. D., & Metz, A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0414 · Cited by 542 · cited 2×
“Nevertheless, disturbances in sexual function due to antidepressants are frequently underestimated in clinical practice because of a lack of direct questioning by the clinician and reluctance by patients to spontaneous self-report (Montejo-Gonzalez et al., 1997; Montejo et al., 2001; Clayton et al. 2002; Haberfellner,…”
BackgroundMontejo-gonzàlez, A. L., Llorca, G., Izquierdo, J. A., Ledesma, A., Bousono, M., Calcedo, A., Carrasco, J. L., Ciudad, J., Daniel, E., De LA Gandara, J., et al. (1997) · Journal of Sex & Marital Therapy · doi:10.1080/00926239708403923 · Cited by 505 · cited 4×
“Treatmentemergent sexual dysfunction occurs with most currently available antidepressants (Montejo-Gonzalez et al., 1997; Montgomery et al. 2002; Clayton and Montejo 2006; Basson et al., 2010) and represents a significant shortcoming due to adverse effects on treatment adherence and episode…”
BackgroundInfluentialGoodwin, G. M., Emsley, R., Rembry, S., Rouillon, F., & the Agomelatine Study Group (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04548 · Cited by 340
Thase, M. E., Haight, B. R., Richard, N., Rockett, C. B., Mitton, M., Modell, J. G., VanMeter, S., Harriett, A. E., & Wang, Y. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0803 · Cited by 304
Hu, X. H., Bull, S. A., Hunkeler, E. M., Ming, E., Lee, J. Y., Fireman, B., & Markson, L. E. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0712 · Cited by 235 · cited 2×
“…available antidepressants (Montejo-Gonzalez et al., 1997; Montgomery et al. 2002; Clayton and Montejo 2006; Basson et al., 2010) and represents a significant shortcoming due to adverse effects on treatment adherence and episode recovery (Coryell et al., 1993; Hu et al., 2004; Papakostas, 2008).”
BackgroundAntidepressant medications: a review of the evidence for drug-induced sexual dysfunction
Montgomery, S. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(01)00313-5 · Cited by 205
Taylor, M. J., Rudkin, L., & Hawton, K. (2005) · Journal of Affective Disorders · doi:10.1016/j.jad.2005.07.006 · Cited by 102
Predictors of Self-Reported Antidepressant Adherence
Burra, T. A., Chen, E., McIntyre, R. S., Grace, S. L., Blackmore, E. R., & Stewart, D. E. (2007) · Behavioral Medicine · doi:10.3200/bmed.32.4.127-134 · Cited by 86 · cited 1×
“Sexual side effects of antidepressants severely impact a patient’s quality of life and jeopardize long-term compliance with treatment (Burra et al., 2007).”
Background
Cited by
Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies
Taylor, D., Sparshatt, A., Varma, S., & Olofinjana, O. (2014) · BMJ · doi:10.1136/bmj.g1888 · Cited by 334
Antidepressant‐induced sexual dysfunction
Rothmore, J. (2020) · Medical Journal of Australia · doi:10.5694/mja2.50522 · Cited by 229
Fornaro, M., McCarthy, M. J., De Berardis, D., Pasquale, D., Martino, Colicchio, Cattaneo, D'Angelo, Fornaro, P., & Tabaton (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s41557 · Cited by 67
Christensen, M. C., Fagiolini, A., Florea, I., Loft, H., Cuomo, A., & Goodwin, G. M. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.07.099 · Cited by 52
Metadata
- Authors
- Montejo, A., Majadas, S., Rizvi, S. J., & Kennedy, S. H.
- Venue
- Human Psychopharmacology: Clinical and Experimental
- Publisher
- Wiley
- Published
- 2011-11-21
- Volume
- 26
- Issue
- 8
- Pages
- 537-542
- ISSN
- 0885-6222 (ISSN-L)
- 1099-1077
- OpenAlex
- W1894568551
- Cited by
- 51
- References
- 8
- FWCI
- 2.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.